NCT06086132 Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
| NCT ID | NCT06086132 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Bologna |
| Condition | Cancer Related Cardiovascular Toxicity |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2025-05-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction
Eligibility Criteria
Inclusion Criteria: * Age 18 years old or older * Capable of giving informed consent * Diagnosis of cancer scheduled for treatment according to treating physician's discretion * Life expectancy \>1 year * For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs Exclusion Criteria: * Age \<18 years old * Not able to give informed consent * Life expectancy \<1 year * Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's
Contact & Investigator
Prof. Olivia Manfrini, MD
PRINCIPAL INVESTIGATOR
University of Bologna
Frequently Asked Questions
Who can join the NCT06086132 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Related Cardiovascular Toxicity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06086132 currently recruiting?
Yes, NCT06086132 is actively recruiting participants. Contact the research team at dimec.epicardio@unibo.it for enrollment information.
Where is the NCT06086132 trial being conducted?
This trial is being conducted at Bologna, Italy, Palermo, Italy, Skopje, North Macedonia, Belgrade, Serbia and 1 additional location.
Who is sponsoring the NCT06086132 clinical trial?
NCT06086132 is sponsored by University of Bologna. The principal investigator is Prof. Olivia Manfrini, MD at University of Bologna. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.